Please assess the completion status of the following clinical trial:

Trial Title: Improving Sleep and Psychological Functioning in People With Depression and Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Score of greater than 10 on the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD-PHQ) telephone screen~* Diagnosis of major depressive episode based on the Structured Clinical Interview for DSM-IV (SCID)~* Score of greater than 20 on the Hamilton Rating Scale for Depression~* Meets research diagnostic criteria for insomnia disorder at least 4 nights per week~* Reported mean sleep latency greater than 30 minutes and mean sleep efficiency less than 85%~* Suitable for outpatient treatment~Exclusion Criteria:~* Use of any psychotropic medications within 2 weeks of initial screening~* Bipolar disorder, schizophrenia, psychotic depression, or any other psychotic disorder~* Uncontrolled asthma or chronic obstructive pulmonary disease~* Chronic pain that may be a significant sleep-disturbing factor~* Uncontrolled thyroid disease~* Poorly controlled diabetes mellitus~* Poorly compensated congestive heart failure~* Currently taking lipophilic beta blockers, opioids, glucocorticoids, theophylline, or other medications known to interfere with sleep~* History of intolerance or treatment resistance to either fluoxetine or eszopiclone~* Inability to abstain from taking any psychotropics other than the study medications during the course of the protocol, including sedating antihistamines~* Use of any herbal or naturopathic treatments for sleep or mood (i.e., St. John's wort, melatonin, kava kava, valerian root, etc.)~* Currently undergoing behavioral, cognitive-behavioral, or interpersonal therapy~* Pregnant or breastfeeding~* Agrees to use an effective form of contraception for the duration of the study~* Uncontrolled symptoms of menopause, including hot flashes~* Uncontrolled hypertension (systolic blood pressure consistently greater than 140 mm Hg, diastolic blood pressure consistently greater than 90 mm Hg)~* Diagnosis of sleep apnea, periodic limb movement disorder, or restless leg syndrome~* Reports habitual bedtime earlier than 9 PM or later than 1 AM more than 2 times per week~* Reports habitual rising time later than 9 AM more than 2 times per week~* Body mass index greater than 30~* Consumes more than 3 alcoholic beverages per day~* Consumes more than 4 caffeinated beverages per day~* Habitual smoking between 11 PM and 7 AM~* Use of illicit drugs~* Score greater than 24 on the Mini Mental State Examination~* Determined to be incompetent~* Determined to be at imminent risk for suicide~* More than 5 lifetime SCID diagnoses of major depressive episodes~* More than 3 failed antidepressant trials during the current episode of depression, as determined by the Antidepressant Treatment History Form~* A course of electroconvulsive therapy during the present depressive episode

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Participants will receive treatment with eszopiclone and fluoxetine
- B (Type: ACTIVE_COMPARATOR): Participants will receive treatment with placebo and fluoxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).